ST-Segment Elevation Myocardial Infarction (STEMI) and Pulmonary Embolism in a Hemophilia A Patient Receiving Emicizumab and recombinant Activated Factor VII

Haemophilia. 2020 Jan;26(1):e5-e8. doi: 10.1111/hae.13871. Epub 2019 Nov 6.

Authors

Krishna Gundabolu¹, Andrew Goldsweig², Vijaya R Bhatt¹, Scott A Koepsell³, James L Harper⁴

Affiliations

¹ Department of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
² Department of Cardiovascular Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
³ Department of Pathology/Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
⁴ Department of Pediatrics-Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE, USA.

PMID: 31694063
DOI: 10.1111/hae.13871

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antibodies, Bispecific / pharmacology
Antibodies, Bispecific / therapeutic use*
Antibodies, Monoclonal, Humanized / pharmacology
Antibodies, Monoclonal, Humanized / therapeutic use*
Factor VIIa / pharmacology
Factor VIIa / therapeutic use*
Hemophilia A / complications*
Hemophilia A / drug therapy*
Humans
Male
Pulmonary Embolism / etiology*
ST Elevation Myocardial Infarction / etiology*

Substances

Antibodies, Bispecific
Antibodies, Monoclonal, Humanized
emicizumab
Factor VIIa

Grants and funding

1 U54GM115458/GM/NIGMS NIH HHS/United States